A single VHH-based toxin-neutralizing agent and an effector antibody protect mice against challenge with Shiga toxins 1 and 2

Infection and Immunity

Volumn 81, Issue 12, 2013, Pages 4592-4603

  Tremblay, Jacqueline M ^a   Mukherjee, Jean ^a   Leysath, Clinton E ^b   Debatis, Michelle ^a   Ofori, Kwasi ^a   Baldwin, Karen ^a   Boucher, Courtney ^a   Peters, Rachel ^a   Beamer, Gillian ^a   Sheoran, Abhineet ^a   Bedenice, Daniela ^a   Tzipori, Saul ^a   Shoemaker, Charles B ^a  

^a TUFTS UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITOXIN; DIFLUPREDNATE; HETERODIMER; MONOCLONAL ANTIBODY; MONOMER; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VEROTOXIN 1; VEROTOXIN 2; VHH HETERODIMER TOXIN NEUTRALIZING AGENT; NANOBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL CELL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; FEMALE; HEAVY CHAIN; HEMOLYTIC UREMIC SYNDROME; IN VIVO STUDY; INTOXICATION; KIDNEY INJURY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; ANIMAL; ENTEROPATHOGENIC ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS;

ANIMALS; ANTIBODIES, MONOCLONAL; ENTEROPATHOGENIC ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HEMOLYTIC-UREMIC SYNDROME; MICE; MOLECULAR SEQUENCE DATA; SHIGA TOXIN 1; SHIGA TOXIN 2; SHIGA-TOXIGENIC ESCHERICHIA COLI; SINGLE-DOMAIN ANTIBODIES;

EID: 84890940453     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01033-13     Document Type: Article

References (40)

1. Buchholz U, Bernard H, Werber D, Bohmer MM, Remschmidt C, Wilking H, Delere Y, an der Heiden M, Adlhoch C, Dreesman J, Ehlers J, Ethelberg S, Faber M, Frank C, Fricke G, Greiner M, Hohle M, Ivarsson S, Jark U, Kirchner M, Koch J, Krause G, Luber P, Rosner B, Stark K, Kuhne M. 2011. German outbreak of Escherichia coli O104:H4 associated with sprouts. N. Engl. J. Med. 365:1763-1770.
2. Frank C, Werber D, Cramer JP, Askar M, Faber M, an der Heiden M, Bernard H, Fruth A, Prager R, Spode A, Wadl M, Zoufaly A, Jordan S, Kemper MJ, Follin P, Muller L, King LA, Rosner B, Buchholz U, Stark K, Krause G. 2011. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N. Engl. J. Med. 365:1771-1780.
3. Karmali MA, Petric M, Lim C, Fleming PC, Arbus GS, Lior H. 1985. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J. Infect. Dis. 151:775-782.
4. Melton-Celsa A, Mohawk K, Teel L, O'Brien A. 2012. Pathogenesis of shiga-toxin producing Escherichia coli. Curr. Top. Microbiol. Immunol. 357:67-103.
5. Boerlin P, McEwen SA, Boerlin-Petzold F, Wilson JB, Johnson RP, Gyles CL. 1999. Associations between virulence factors of Shiga toxinproducing Escherichia coli and disease in humans. J. Clin. Microbiol. 37:497-503.
6. Friedrich AW, Bielaszewska M, Zhang WL, Pulz M, Kuczius T, Ammon A, Karch H. 2002. Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. J. Infect. Dis. 185:74-84.
7. Hedican EB, Medus C, Besser JM, Juni BA, Koziol B, Taylor C, Smith KE. 2009. Characteristics of O157 versus non-O157 Shiga toxinproducing Escherichia coli infections in Minnesota, 2000-2006. Clin. Infect. Dis. 49:358-364.
8. Kawano K, Okada M, Haga T, Maeda K, Goto Y. 2008. Relationship between pathogenicity for humans and stx genotype in Shiga toxinproducing Escherichia coli serotype O157. Eur. J. Clin. Microbiol. Infect. Dis. 27:227-232.
9. Lingwood CA, Law H, Richardson S, Petric M, Brunton JL, De Grandis S, Karmali M. 1987. Glycolipid binding of purified and recombinant Escherichia coli produced verotoxin in vitro. J. Biol. Chem. 262:8834-8839.
10. Cohen A, Hannigan GE, Williams BR, Lingwood CA. 1987. Roles of globotriosyl- and galabiosylceramide in verotoxin binding and high affinity interferon receptor. J. Biol. Chem. 262:17088-17091.
11. Johannes L, Romer W. 2010. Shiga toxins-from cell biology to biomedical applications. Nat. Rev. Microbiol. 8:105-116.
12. Spooner RA, Lord JM. 2012. How ricin and Shiga toxin reach the cytosol of target cells: retrotranslocation from the endoplasmic reticulum. Curr. Top. Microbiol. Immunol. 357:19-40.
13. O'Brien AD, Tesh VL, Donohue-Rolfe A, Jackson MP, Olsnes S, Sandvig K, Lindberg AA, Keusch GT. 1992. Shiga toxin: biochemistry, genetics, mode of action, and role in pathogenesis. Curr. Top. Microbiol. Immunol. 180:65-94.
14. Cherla RP, Lee SY, Tesh VL. 2003. Shiga toxins and apoptosis. FEMS Microbiol. Lett. 228:159-166.
15. Obrig TG, Louise CB, Lingwood CA, Boyd B, Barley-Maloney L, Daniel TO. 1993. Endothelial heterogeneity in Shiga toxin receptors and responses. J. Biol. Chem. 268:15484-15488.
16. Psotka MA, Obata F, Kolling GL, Gross LK, Saleem MA, Satchell SC, Mathieson PW, Obrig TG. 2009. Shiga toxin 2 targets the murine renal collecting duct epithelium. Infect. Immun. 77:959-969.
17. Zoja C, Buelli S, Morigi M. 2010. Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction. Pediatr. Nephrol. 25:2231-2240.
18. Wong CS, Mooney JC, Brandt JR, Staples AO, Jelacic S, Boster DR, Watkins SL, Tarr PI. 2012. Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis. Clin. Infect. Dis. 55:33-41.
19. Hunt JM. 2010. Shiga toxin-producing Escherichia coli (STEC). Clin. Lab Med. 30:21-45.
20. Yamagami S, Motoki M, Kimura T, Izumi H, Takeda T, Katsuura Y, Matsumoto Y. 2001. Efficacy of postinfection treatment with anti-Shiga toxin (Stx) 2 humanized monoclonal antibody TMA-15 in mice lethally challenged with Stx-producing Escherichia coli. J. Infect. Dis. 184:738-742.
21. Mukherjee J, Chios K, Fishwild D, Hudson D, O'Donnell S, Rich SM, Donohue-Rolfe A, Tzipori S. 2002. Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection. Infect. Immun. 70:612-619.
22. Mukherjee J, Chios K, Fishwild D, Hudson D, O'Donnell S, Rich SM, Donohue-Rolfe A, Tzipori S. 2002. Production and characterization of protective human antibodies against Shiga toxin 1. Infect. Immun. 70: 5896-5899.
23. Tzipori S, Sheoran A, Akiyoshi D, Donohue-Rolfe A, Trachtman H. 2004. Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome. Clin. Microbiol. Rev. 17:926-941, table of contents.
24. Dowling TC, Chavaillaz PA, Young DG, Melton-Celsa A, O'Brien A, Thuning-Roberson C, Edelman R, Tacket CO. 2005. Phase 1 safety and pharmacokinetic study of chimeric murine-human monoclonal antibody c alpha Stx2 administered intravenously to healthy adult volunteers. Antimicrob. Agents Chemother. 49:1808-1812.
25. Sauter KA, Melton-Celsa AR, Larkin K, Troxell ML, O'Brien AD, Magun BE. 2008. Mouse model of hemolytic-uremic syndrome caused by endotoxin-free Shiga toxin 2 (Stx2) and protection from lethal outcome by anti-Stx2 antibody. Infect. Immun. 76:4469-4478.
26. Davies KA, Robson MG, Peters AM, Norsworthy P, Nash JT, Walport MJ. 2002. Defective Fc-dependent processing of immune complexes in patients with systemic lupus erythematosus. Arthritis Rheum. 46:1028-1038.
27. Lovdal T, Andersen E, Brech A, Berg T. 2000. Fc receptor mediated endocytosis of small soluble immunoglobulin G immune complexes in Kupffer and endothelial cells from rat liver. J. Cell Sci. 113(Part 18):3255-3266.
28. Mukherjee J, Tremblay JM, Leysath CE, Ofori K, Baldwin K, Feng X, Bedenice D, Webb RP, Wright PM, Smith LA, Tzipori S, Shoemaker CB. 2012. A novel strategy for development of recombinant antitoxin therapeutics tested in a mouse botulism model. PLoS One 7:e29941. doi: 10.1371/journal.pone.0029941.
29. Gibbs WW. 2005. Nanobodies. Sci. Am. 293:78-83.
30. Sepulveda J, Mukherjee J, Tzipori S, Simpson LL, Shoemaker CB. 2010. Efficient serum clearance of botulinum neurotoxin achieved using a pool of small antitoxin binding agents. Infect. Immun. 78:756-763.
31. Jacewicz MS, Acheson DW, Binion DG, West GA, Lincicome LL, Fiocchi C, Keusch GT. 1999. Responses of human intestinal microvascular endothelial cells to Shiga toxins 1 and 2 and pathogenesis of hemorrhagic colitis. Infect. Immun. 67:1439-1444.
32. Donohue-Rolfe A, Acheson DW, Kane AV, Keusch GT. 1989. Purification of Shiga toxin and Shiga-like toxins I and II by receptor analog affinity chromatography with immobilized P1 glycoprotein and production of cross-reactive monoclonal antibodies. Infect. Immun. 57:3888-3893.
33. Tremblay JM, Kuo CL, Abeijon C, Sepulveda J, Oyler G, Hu X, Jin MM, Shoemaker CB. 2010. Camelid single domain antibodies (VHHs) as neuronal cell intrabody binding agents and inhibitors of Clostridium botulinum neurotoxin (BoNT) proteases. Toxicon 56:990-998.
34. Maass DR, Harrison GB, Grant WN, Shoemaker CB. 2007. Three surface antigens dominate the mucosal antibody response to gastrointestinal L3-stage strongylid nematodes in field immune sheep. Int. J. Parasitol. 37:953-962.
35. Sheoran AS, Chapman-Bonofiglio S, Harvey BR, Mukherjee J, Georgiou G, Donohue-Rolfe A, Tzipori S. 2005. Human antibody against Shiga toxin 2 administered to piglets after the onset of diarrhea due to Escherichia coli O157:H7 prevents fatal systemic complications. Infect. Immun. 73:4607-4613.
36. Chow SK, Casadevall A. 2012. Monoclonal antibodies and toxins-a perspective on function and isotype. Toxins (Basel) 4:430-454.
37. Wesolowski J, Alzogaray V, Reyelt J, Unger M, Juarez K, Urrutia M, CauerhffA, Danquah W, Rissiek B, Scheuplein F, Schwarz N, Adriouch S, Boyer O, Seman M, Licea A, Serreze DV, Goldbaum FA, Haag F, Koch-Nolte F. 2009. Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Med. Microbiol. Immunol. 198:157-174.
38. Tarr PI, Gordon CA, Chandler WL. 2005. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 365:1073-1086.
39. Vandenbroucke K, de Haard H, Beirnaert E, Dreier T, Lauwereys M, Huyck L, Van Huysse J, Demetter P, Steidler L, Remaut E, Cuvelier C, Rottiers P. 2010. Orally administered L. lactis secreting an anti-TNF nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol. 3:49-56.
40. Maass DR, Sepulveda J, Pernthaner A, Shoemaker CB. 2007. Alpaca (Lama pacos) as a convenient source of recombinant camelid heavy chain antibodies (VHHs). J. Immunol. Methods 324:13-25.